Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
Ulrich Pecks, Head of Obstetrics and Maternal Health and Fetal Development at University Hospital Würzburg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“In addition to our recent publication on VTE prophylaxis after CS in JPM we are proud of our accepted review in Archives which provides an overview of guidelines for hereditary thrombophilia in pregnancy.
Key points:
- Pregnant women with inherited thrombophilia have a significantly higher risk of venous thromboembolism (VTE), up to approximately 40-fold depending on type and history.
Risk classification:
- Low risk: e.g., heterozygous factor V Leiden or prothrombin mutation
- High risk: e.g., homozygous mutations, combined thrombophilia, severe antithrombin/protein C/S deficiency
Guidelines vary:
International recommendations for thromboprophylaxis differ widely – no universal standard.
Use of prophylaxis (heparin):
Generally recommended for high-risk thrombophilia (during pregnancy and 6 weeks postpartum).
For low-risk, only if additional risk factors or positive family history are present.
Limited evidence:
There is no strong evidence from randomized controlled trials proving that pharmacological prophylaxis significantly reduces VTE risk.
Risk–benefit balance:
Prophylaxis carries risks (e.g., bleeding), and VTE risk may be overestimated – possible overtreatment.
Individualized decision-making:
Management should be case-by-case, considering individual risk profile, history, and patient preference.
Bottom line:
Although VTE risk is increased in pregnant women with thrombophilia, inconsistent guidelines and limited evidence mean that prophylaxis decisions must be individualized.”
Title: Recommendations from guidelines for the prevention of venous thromboembolism in pregnant women with inherited thrombophilia
Authors: Werner Rath, Panagiotis Tsikouras, Ulrich Pecks
Read the Full Article on Archives of Gynecology and Obstetrics.
Stay updated on all scientific advances with Hemostasis Today.
-
May 19, 2026, 20:00Christoph B. Olivier: CYP2C19 Genotype, Platelet Reactivity and Risk Stratification in AF Patients Undergoing PCI
-
May 19, 2026, 16:41Selina Marwa: Strengthening Sickle Cell Disease Prevention and Care in Africa
-
May 19, 2026, 16:34Congratulations to the NNHF Project of the Year 2026 Winner
-
May 19, 2026, 16:32Veronica Sanchez: Early Screening Matters in CKM Syndrome
-
May 19, 2026, 16:24Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A
-
May 19, 2026, 16:15Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
-
May 19, 2026, 16:10Anirban Sen Gupta: Lyophilized Synthetic Platelets as a Stable Powder for Rapid Hemorrhage Control
-
May 19, 2026, 16:02Stroke Foundation Contributes to National Roundtable on Women’s Cardiovascular Health
-
May 19, 2026, 15:57Explore the Emerging Science Behind Factor XI/XIa Inhibition on the ISTH Academy – ISTH